2025-02-19Niranjan Ghatule
US President Donald Trump’s proposal to impose a 25% tariff on pharmaceutical imports could significantly impact Indian pharma companies, which heavily rely on the US market for their revenues. With companies like Aurobindo Pharma and Dr. Reddy's Laboratories generating nearly half of their income from the US, the financial implications could be substantial.
View more
Your experience on this site will be improved by allowing cookies
Cookie Policy
